. Owing to the cytotoxic, teratogenic and carcinogenic effects that are caused by alkylation damage, alkylating agents pose considerable threats to human health 6 . In spite of this, certain toxic alkylating agents are commonly used systemically as chemotherapeutic drugs in cancer patients, with the goal of killing cancer cells 7 . Consequently, although alkylating agents can induce cancer, they are also used to treat cancer. On the basis of the double-edged properties of alkylating agents, a greater understanding of the cellular factors that determine biological outcome in response to alkylation damage is particularly relevant for both cancer prevention and cancer therapy, in addition to general human health. The biological response to alkylating agents can be complex owing to the variety of lesions that are introduced by a single alkylating agent in combination with the diversity of cellular repair mechanisms and response pathways that can be elicited on alkylation damage. In this Review, we focus on the interplay between the multiple cellular factors that respond to DNA alkylation damage and how they collectively determine sensitivity or resistance to alkylating agents.
Molecular damage caused by alkylating agents
Alkylating agents react with the ring nitrogens (N) and extracyclic oxygen (O) atoms of DNA bases to generate a variety of covalent adducts that range from simple methyl groups to complex alkyl additions 8, 9 (FIGS 1,2).
The pattern of DNA lesions generated by an alkylating agent depends on the number of reactive sites within the alkylating agent (monofunctional versus bifunctional), its particular chemical reactivity (S N 1-type versus S N 2-type nucleophilic substitution), the type of alkyl group addition (methyl or chloroethyl and so on) and the DNA substrate (double-stranded or single-stranded). Monofunctional alkylating agents contain one active chemical moiety for the modification of a single site in DNA, whereas bifunctional alkylating agents contain two reactive groups that can bond to separate DNA bases to form interstrand crosslinks. Whereas S N 2-alkylating agents mainly target ring nitrogen atoms in DNA bases, S N 1-alkylating agents can modify these nitrogens plus the extracyclic oxygen groups (FIG. 1) . Notably, nearly all chemotherapeutic alkylating drugs that are currently used in the clinic are S N 1-type and they can be either monofunctional or bifunctional (FIG. 2) .
Owing to the high nucleophilic reactivity of the N7-position of guanine in DNA, most monofunctional methylating agents induce the formation of N7-methyl guanine (7meG) as the predominant methylation adduct, which accounts for 60-80% of the total alkylation lesions in DNA (FIG. 1) . By itself, 7meG does not possess any mutagenic or cytotoxic properties but it is prone to spontaneous depurination to form an apurinic (AP) site that is toxic and mutagenic. In addition to 7meG, monofunctional methylating agents can generate N3-methyladenine (3meA) as the other primary N-methylation product, which accounts for 10-20% of the total methyl adducts 9 . In contrast to the fairly innocuous 7meG lesion, the 3meA lesion is highly cytotoxic, as it can block most DNA polymerases and thereby inhibit DNA synthesis 10, 11 . In single-stranded DNA, the N1-position of adenine and the N3-position of cytosine are also subject to methylation by monofunctional methylating agents to generate the replication-blocking and mispairing lesions, 1-methyladenine (1meA) and 3-methylcytosine (3meC) 8 (FIG. 1) . In double-stranded DNA, these sites are protected by base pairing, but they can be transiently exposed during replication, transcription or recombination.
Amongst the oxygen atoms of DNA, the O 6 -position of guanine is a major site of methylation by S N 1-type alkylating agents for generating O 6 -methylguanine (O 6 meG) (FIG. 1) . Even though O-alkyl lesions are generated to a much lesser extent than N-alkyl adducts, the induction of O 6 meG lesions by alkylating agents is of great biological relevance because O 6 meG can readily mispair with thymine during DNA replication to cause many of the mutagenic and cytotoxic biological effects of alkylating agents (discussed below). Alkylating agents can also modify other nitrogen and oxygen atoms in DNA to generate additional toxic and mutagenic lesions (FIG. 1) . However, these lesions are observed at tenfold to 100-fold lower levels than the lesions mentioned above and represent a small proportion of total alkylation adducts.
Several monofunctional S N 1-methylating agents are currently used as anticancer drugs; these include the triazine family of compounds such as dacarbazine, procarbazine and temozolomide, as well as the nitro sourea compound streptozotocin 7 (FIG. 2) . Owing to their chemical reactivity as monofunctional S N 1-methylating agents, these chemotherapeutic alkylating agents produce substantial levels of 7meG, 3meA and O 6 meG as the primary alkylated DNA adducts. The chloro ethylating agents represent another major class of monofunctional alkylating agents that react with DNA at a similar specificity to S N 1-methylating agents except with the addition of a chloroethyl group. Most nitrosourea compounds that are used in the clinic are chloro ethy lating agents that can modify the N7 and O 6 -positions of guanine to generate chloroethyl adducts (FIG. 2) . Importantly, O 6 -chloroethyl guanine (O 6 Cl-ethylG) adducts undergo rapid chemical rearrangement to react with nearby cytosine bases to generate guanine-cytosine (G-C) interstrand crosslinks that are highly cytotoxic.
Bifunctional alkylating agents have similar reactive properties to monofunctional alkylating agents but contain two active moieties that can react with separate bases of DNA to form interstrand crosslinks in addition to monoadducts (FIG. 2) . The nitrogen mustards and aziridine compounds are two major classes of bifunctional alkylating drugs used for cancer treatment that can crosslink DNA through an aziridinium-ring intermediate 12 . Nitrogen mustard compounds react readily with N7-guanine and, to a lesser extent, with N3-adenine and N7-adenine to form bulky N-monoadducts. These adducts can subsequently react with another base to form guanine-guanine (G-G) and guanine-adenine (G-A) interstrand crosslinks (FIG. 2) . The nitrogen mustard mechloroethamine was the first chemotherapeutic drug used on cancer patients, and its derivatives (chlorambucil, cyclophosphamide, melphalan and bendamustine) are prescribed for the treatment of a wide variety of cancers. Aziridine compounds such as altretamine, mitomycin C and thiotepa use a reaction similar to nitrogen mustards to form G-G or G-A interstrand crosslinks, in addition to a variety of monoadducts.
Depending on their position in DNA, the different base adducts that are introduced by alkylating agents can compromise genome integrity by inducing mutagenesis (thereby promoting cancer induction) and/or by blocking essential biological processes such as DNA replication and transcription (which could potentially lead to cell death) (FIG. 1) . Moreover, certain lesions can also be processed into clastogenic and cytotoxic products that can engage other DNA repair pathways or that can induce programmed cell death. Although in this Review we focus on the biological effects of alkylation damage to genomic DNA, it is important to note that other biological molecules are also subject to alkylation damage, including RNA, protein, lipids and mitochondrial DNA. Thus, a single chemotherapeutic alkylating agent can modify a variety of biological molecules to generate a range of lesions that can elicit a number of biological effects.
Complex responses to DNA alkylation damage Just as a single alkylating agent can cause multiple types of alkylated base lesions, each lesion can be repaired or processed by several enzymes and pathways in an effort to counteract the genomic damage that is induced by alkylating agents, and to protect an organism from alkylation toxicity and mutagenesis (FIG. 3) . Thus, diverse cellular repair pathways collectively modulate
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alkylation sensitivity. This occurs through an overlap in substrates, compensating pathways, processing of intermediates by alternative pathways or through direct crosstalk between pathways. The major repair mechanisms for alkylation damage include direct DNA repair by members of the AlkB homologue (ALKBH) family of α-ketoglutarate-dependent dioxygenase enzymes and the O 6 -methylguanine-DNA methyltransferase (MGMT) repair protein; and by the multistep pathways of base excision repair (BER) and nucleotide excision repair (NER) (FIG. 4) . ALKB catalyses direct reversal of certain N-alkyl lesions (for example, 1meA and 3meC) through a unique oxidative dealkylation reaction, whereas MGMT directly repairs O 6 meG and O 6 ClethylG lesions through transfer of the alkyl group to its active site cysteine residue 13 . The BER pathway has an important role in the repair of many N-alkyl lesions (for example, 3meA and 7meG), and the NER pathway may also contribute to the repair of alkylated base lesions 14, 15 , although this pathway is primarily thought to function in the repair of bulkier base lesions that substantially disrupt DNA-helix structure (such as intrastrand crosslinks and ultraviolet radiation-induced DNA damage) 16 . Numerous additional repair pathways have important roles in the cellular response to alkylating agents by processing or through bypassing the downstream DNA lesions that result from DNA transactions at the primary alkyl lesion (for example, DNA mispairs and replication blocks) or from repairing secondary lesions (such as single-strand DNA breaks (SSBs), double-strand DNA breaks (DSBs) and crosslinks) (FIGS 3, 4) . The mismatch repair (MMR) pathway recognizes and processes DNA base mismatches to remove misincorporated nucleotides; this includes the O 6 meG:T mispairs that arise by the incorporation of thymine opposite O 6 meG during replication of alkylated DNA 17 . Both the homologous recombination (HR) and non-homologous end joining (NHEJ) pathways repair DSBs; HR uses homologous DNA (sister chromatids) as a template to resynthesize DNA across the break, which results in sister chromatid exchanges (SCEs); whereas, NHEJ joins the DNA ends with little or no homology. The translesion DNA synthesis (TLS) pathway uses low-fidelity DNA polymerases to bypass lesions that stall high-fidelity replicative polymerases, thereby alleviating any blocks during DNA replication. Importantly, HR generally results in error-free repair, whereas NHEJ and TLS are usually error-prone repair mechanisms that can give rise to mutations. Finally, the Fanconi anaemia pathway coordinates elements of NER, HR and TLS to function in the replication-dependent repair of interstrand crosslinks that are caused by particular alkylating agents. Owing to their widespread involvement in the response to DNA alkylation damage, we highlight the roles of these DNA repair mechanisms throughout this Review and refer readers to more comprehensive reviews dedicated to these pathways [18] [19] [20] . With the abundance of repair pathways that act on DNA alkylation damage, it has become clear that an imbalance in any one pathway can affect the overall cellular response, resulting in dramatic effects on the alkylation sensitivity of a cell, a tissue or a whole organism. Moreover, pathways such as BER and NER require the coordination of multiple enzymatic steps in order to be completed accurately. If an imbalance occurs such that the steps lose coordination, toxic intermediates accumulate that are often more toxic than the original DNA base lesion. Furthermore, just as imbalances can occur within a particular DNA repair pathway, they can also occur between different pathways. In this Review, we focus on the distinct and overlapping pathways that are involved in the repair of 3meA and O 6 meG -two Deleterious consequences of BER imbalance BER is a highly coordinated, multistep pathway that removes a damaged DNA base (such as an alkylated base) and replaces it with the correct base (FIGS 3, 5) . The initiation of BER occurs by the recognition and excision of a damaged DNA base by a DNA glycosylase. In humans, there are currently 11 known DNA glycosylases 21 .
Here, we focus on alkyladenine-DNA glyco sylase (AAG; also known as MPG and ANPG) as it is responsible for excising the cytotoxic 3meA DNA lesion that is induced by both S N 1-and S N 2-alkylating agents. Importantly, every step of BER generates intermediates (AP sites, 5′-deoxyribose phosphate (5′-dRP) residues and SSBs), which have been shown to be both mutagenic and toxic (FIGS 3, 5) . In fact, the BER intermediates are often more toxic than the initiating DNA base lesion (in this case, 3meA, which is a replication-blocking lesion), presumably because translesion DNA polymerases are capable of bypassing the unrepaired 3meA lesion with varying efficiency and accuracy 10, [22] [23] [24] . Thus, it is essential for BER to be tightly controlled to avoid an accumulation of any of these toxic intermediates. Indeed, another key BER protein, XRCC1, coordinates the DNA-processing events of BER by interacting with each of the aforementioned DNA-processing enzymes to ensure the proper completion of BER. Accordingly, it has been proposed that the BER pathway functions similarly to 'passing the baton' in a relay race: one enzyme complex passes the repair intermediates to the next enzyme complex, essentially sequestering the intermediates and preventing their toxicity 25, 26 . Therefore, an imbalance in any step can alter the phenotypic response to alkylating agents; imbalances can occur when a BER enzyme exhibits an alteration in activity or expression level without compensating changes in the downstream steps of the BER pathway. Although single nucleotide polymorphisms (SNPs) found in genes encoding the BER proteins have been associated with an increased risk of multiple types of cancer, additional studies are required to determine the functional consequences and the importance of these SNPs in cancer patients (TABLE 1) . However, the potential for imbalanced BER in human cancer is exemplified by the colorectal cancer predisposition syndrome, MYH-associated polyposis (MAP), which is a consequence of biallelic inherited mutations in the DNA glycosyslase MYH (also known as MUTYH) 27, 28 (TABLE 1) .
BER imbalance in vivo results in detrimental consequences. The modulation of DNA glycosylase activity can have profound effects if the downstream BER pathway is not properly coordinated [29] [30] [31] [32] . Pioneering studies in bacteria and yeast have shown that increased DNA glycosylase levels are correlated with increased spontaneous mutagenesis and enhanced sensitivity to the alkylating agent methyl methanesulphonate (MMS) [33] [34] [35] [36] . This AAG-dependent increase in sensitivity to alkylation has been recapitulated 
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in numerous mammalian cell types, including breast and ovarian cancer cells, astrocytes and mouse embryonic fibroblasts (MEFs) 31, 32, [37] [38] [39] [40] . Moreover, increased expression of AAG in mammalian cells also results in increased SCEs, chromosome aberrations, inhibition of DNA replication and a higher number of DNA breaks after treatment with alkylating agents 41 . Even in the absence of alkylating agents, increased AAG DNA glycosylase activity can lead to detrimental effects; AAG activity is correlated with microsatellite instability and increased spontaneous frameshift mutagenesis in yeast and human cells, as well as in noncancerous human tissue samples 42, 43 . Consequently, evidence suggests that altered AAG expression may have a role in various human cancers [44] [45] [46] [47] (TABLE 1) .
The generation of both an Aag (also known as Mpg)-knockout mouse and a transgenic mouse with increased AAG levels (AAG-Tg) has provided valuable models to test the consequences of BER imbalance at the wholeanimal level 30, 48, 49 (TABLE 2) . As AAG-initiated BER can result in the generation of toxic intermediates following treatment with MMS in certain wild-type cells, increased AAG activity would promote the accumulation of toxic intermediates, whereas loss of AAG would protect against the formation of these intermediates. Thus, sensitivity to alkylating agents between wild-type, Aag -/-and AAG-Tg mouse models would be predicted to correlate with AAG activity levels (that is, sensitivity to alkylating agents could be described as AAG-Tg > wild-type > Aag -/-). Indeed, this pattern of AAG-driven toxicity has been repeatedly observed in multiple tissues (TABLE 2) . For example, ex vivo bone marrow cell survival assays have shown that Aag -/-myeloid precursor cells are resistant, whereas AAG-Tg cells are ultra-sensitive, to alkylating agents compared with wild-type cells 50 (L.D.S., unpublished observations). Moreover, AAG-Tg mice exhibit vastly increased MMSinduced toxicity in numerous tissues, including spleen, thymus, retina and cerebellum, compared with wild-type or Aag -/-mice 30 (L.D.S., unpublished observations)
. -methylguanine DNA methyltransferase (MGMT) catalyses the transfer of the aberrant methyl group onto a cysteine in the active site of MGMT, thereby removing the lesion from DNA. The AlkB homologue (ALKBH) family of α-ketoglutarate-dependent dioxygenases catalyse the hydroxylation of the aberrant methyl group, which then spontaneously leaves as formaldehyde (HCOH) to regenerate the normal base. b | The base excision repair (BER) pathway removes simple alkyl and oxidative base lesions. BER is initiated by a DNA glycosylase, such as alkyladenine-DNA glycosylase (AAG), which excises the damaged base to generate an abasic site for subsequent processing by either short-patch BER or long-patch BER (not shown). In short-patch BER, the apurinic-apyrimidinic endonuclease (APE) incises the abasic site to yield a 3′ OH adjacent to a 5′-deoxyribose phosphate (5′-dRP) moiety. DNA polymerase β (Pol β) removes the 5′-dRP and replicates DNA from the 3′ OH, generating a nick ready for subsequent ligation by DNA ligase (LIG). Long-patch repair occurs in a similar manner except that a longer piece of DNA is removed. c | Nucleotide excision repair (NER) removes bulky, helix-distorting lesions but it can also serve as a backup repair mechanism for the excision of certain alkylated bases 16 . NER is initiated by the recognition of a distorted region containing the DNA adducts followed by a 5′ and 3′ incision on either side of the lesion to create a 27-29 nucleotide gap. The excised region is then filled in by Pol δ or Pol ε for subsequent ligation. d | The mismatch repair (MMR) pathway mediates the removal of mismatched bases, as well as mispairs that are caused by base alkylation lesions such as O 6 meG:T. In mammals, MMR is initiated by the recognition of mismatches by the MUTSα heterodimer (MSH2-MSH6) followed by recruitment of the MUTLα heterodimer (PMS2-MLH1). Diffusion of MUTSα-MUTLα leads to nicking of the DNA either upstream or downstream of the mismatch; this serves as an entry point for exonuclease 1 (EXO1) that removes a segment of DNA. This is subsequently filled in and repaired by a combination of Pol δ, Pol ε and LIG to complete repair. TFIIH, transcription factor IIH; XP, xeroderma pigmentosum protein. Finally, Aag -/-mice also exhibit remarkable protection against pancreatic β-cell death after a single high dose of the β-cell-specific alkylating agent streptozotocin, as well as a marked delay in the development of streptozotocininduced glucose intolerance and diabetes 51, 52 . Thus, in general, alkylating agents are much more toxic in AAG-Tg mice, whereas Aag -/-mice are either resistant or display no dramatic difference in sensitivity compared with wild-type mice in response to alkylating agents 50 . Although complete inhibition of BER initiation (as observed in Aag -/-mice) protects against alkylationmediated cell death in numerous tissues, it is important to note that BER inhibition does not confer protection to all alkylating agents or cell types. For example, Aag -/-embryonic stem cells, as well as MEFs with reduced levels of AAG, are actually sensitized to alkylating agents 49, 53, 54 . Furthermore, Aag -/-mice are more susceptible than wild-type mice to alkylation-induced colon cancer that is initiated by the alkylating agent azoxymethane (AOM) in combination with the inflammatory agent dextran sodium sulphate (DSS). This indicates that loss of AAG can protect against toxicity but not necessarily against carcinogenesis 55, 56 (TABLE 2) . Moreover, it is unknown why only some cells and tissues are sensitive to AAG-mediated alkylation toxicity. For example, the MMS-mediated retinal degeneration that is observed in mice only occurs in the photoreceptor cells of the outer nuclear layer and does not occur in the adjacent layers of the retina 30 . Although it is possible that different tissues might receive different doses of an alkylating agent, leading to differential toxicity, most of the aforementioned alkylating agents act directly, without the need for metabolic activation. Instead, it is more likely that insufficient activity of downstream BER enzymes in the sensitive cell types causes an accumulation of toxic BER intermediates, which triggers the majority of AAG-dependent cell death in wild-type and AAG-Tg mice.
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Imbalancing the BER pathway at points downstream of the initiating DNA glycosylase can also sensitize cells to alkylating agents 57 . For example, if AP endonuclease (APE; also known as APEX1) is limiting for the repair of AP sites either because glycosylase levels are too high or because APE levels are too low, then the consequence is an accumulation of mutagenic and cytotoxic AP sites and the subsequent generation of mutations and strand breaks during replication 34, 58, 59 (FIG. 5) . Additionally, inducing BER imbalance through APE inhibition (either by RNA interference or by chemical inhibitors) produces similar deleterious results by increasing the number of toxic AP sites and by enhancing the sensitivity of numerous cell types to alkylating agents 57, [60] [61] [62] [63] . Likewise, the inhibition of DNA polymerase β (Pol β) can also imbalance the BER pathway, leading to severe biological consequences. For example, MEFs lacking Pol β have normal viability and growth characteristics but exhibit sensitivity to alkylating agents 64 . Even partial inhibition of Pol β modulates sensitivity to alkylating agents: a 50% reduction in Pol β levels, as observed in Polb +/-mice, results in increased SSBs, chromosome aberrations and mutagenicity compared with wild-type mice 65 . Importantly, loss of AAG expression in Polb-deficient cells can rescue their sensitivity to alkylating agents, illustrating that the MMS-mediated hypersensitivity and mutagenesis in Polb-deficient cells is AAG-dependent. The ability of double-mutant MEFs (which lack both AAG and Pol β) to survive alkylating agent exposure indicates that 3meA and other AAG substrates can be bypassed and tolerated by these cells during DNA replication, presumably by the TLS pathway 10, 24, 66, 67 (FIG. 5) . However, if AAG excises 3meA to initiate BER, then downstream BER enzymes such as Pol β are required to complete BER to prevent an accumulation of toxic BER intermediates 31, 68 . In addition to being a DNA polymerase, Pol β possesses an intrinsic DNA lyase activity that excises 5′-dRP residues in DNA (FIG. 5) . Mutational analysis has revealed that the 5′-dRP lyase activity of Pol β is also required for alkylation resistance, because disabling only the 5′-dRP lyase function of Pol β is sufficient to confer alkylation sensitivity 69 . This finding is notable because it confirms that the 5′-dRP species is a toxic BER intermediate. It also demonstrates that, unlike the polymerase function of Pol β, there is no redundant pathway for the 5′-dRP removal by Pol β, at least in MEFs. Interestingly, another variant Monofunctional methylating agents induce the formation of 3-methyladenine (3meA), which is excised by the alkyladenine-DNA glycosylase (AAG) to generate an apurinic site (AP). The AP endonuclease (APE) incises the DNA backbone immediately 5′ to the AP site, generating a single-strand break (SSB) containing a 3-hydroxyl (3′ OH) and a 5′-deoxyribose phosphate (5′-dRP). DNA polymerase β (Pol β) removes the 5′-dRP moiety through intrinsic lyase activity and fills in the resulting gap. The nick is then sealed by DNA ligase (LIG) to complete base excision repair (BER). If BER is inhibited, or downstream steps of BER are limiting, then toxic intermediates can accumulate, leading to blocks to DNA replication, replication fork collapse, double-strand DNA breaks (DSBs) and eventual cell death. The translesion DNA synthesis (TLS), homologous recombination (HR) and non-homologous end-joining (NHEJ) pathways can bypass or repair secondary damage that is caused by alkyl lesions in order to promote cell survival at the expense of mutation or sister chromatid exchange (SCE).
of Pol β that is expressed in some human cancers (Pol βΔ), is known to have a dominant-negative function that essentially inhibits BER 70 . By inhibiting BER, Pol βΔ-expressing cells exhibit increased sensitivity to the alkylating agent methylnitrosourea (MNU), and Pol βΔ-transgenic mice exhibit greater susceptibility to MNU-induced mammary tumorigenesis than wild-type mice 70 . To further underscore the importance of balance within the BER pathway, increased Pol β activity can also result in deleterious consequences because an increased rate of spontaneous frameshift mutagenesis and microsatellite instability is observed following increased Pol β expression 71, 72 . Thus, perturbation of either Pol β activity or function in the cell can cause a BER imbalance, leading to increased cancer susceptibility and enhanced alkylation sensitivity.
As noted above, the XRCC1 scaffold protein has a major role in coordinating BER by interacting with the aforementioned DNA-processing enzymes at sites of alkylation damage 73 . Not surprisingly, repression of XRCC1 results in BER imbalance and alkylation sensitivity. For example, Xrcc1-deficient cells exhibit impaired BER and accumulate SSBs after treatment with an alkylating agent 74 . Consequently, Xrcc1-deficient cells exhibit severe hypersensitivity to numerous alkylating agents, as well as increased genomic instability 75, 76 . Of note, human monocytes lack detectable levels of XRCC1 and are hypersensitive to alkylating agents 77 , which indicates that specific human cell populations can be deficient in BER. Collectively, these data demonstrate that the initiation of the BER pathway by alkylating agents results in an accumulation of toxic and mutagenic BER intermediates that, if uncontrolled, can result in cell death.
The alteration of various BER proteins in cancer patients emphasizes the possibility that imbalanced BER may have a role in cancer aetiology (TABLE 1) . Indeed, certain polymorphisms in APEX1, as well as alterations in APE expression or subcellular localization, can be either a risk factor or a prognostic indicator for numerous human cancers [78] [79] [80] [81] [82] [83] . Further, alterations in Pol β are observed in as many as 30% of human cancers 84 , whereas polymorphisms in XRCC1 are linked to an increased risk of numerous types of cancer 85 (TABLE 1) . Thus, a more detailed understanding of how the generation of toxic BER intermediates is regulated in different cell types, both normal and cancerous, will surely contribute to improved cancer chemotherapy with alkylating agents. Chemical modulation of BER for improved chemotherapy. Inhibitors of BER are being vigorously explored as a mechanism for potentiating the response of cancer cells to alkylating agents. Several inhibitors of APE activity have been identified that sensitize a variety of human cell types to alkylating agents; methoxyamine is one such APE inhibitor that is currently being used in the clinic [86] [87] [88] (reviewed in REF. 32 ). Methoxyamine blocks BER by reacting with an aldehyde-sugar group of the AP site, causing a stable methoxyamine-AP-intermediate adduct that blocks the endonuclease activity of APE. By inhibiting the proper completion of BER, methoxyamine has been shown to potentiate the cytotoxicity of numerous alkylating agents in a variety of cancer cell types and tumour xenograft models 32, 62, 89 . In addition to altering the APE substrate to prevent DNA incision, direct inhibition of APE could also achieve the same end point of blocking BER. However, given that APE also has an important role in maintaining certain transcription factors, including nuclear factor-κB and p53, in an active reduced state, care must be taken to inhibit only the DNA repair function of APE to prevent off-target effects 90, 91 . Small-molecule inhibitors of Pol β represent another strategy for effectively imbalancing the BER pathway 92 . As expected from the characterization of Polb-deficient cells, Pol β inhibitors can increase cellular sensitivity to a variety of alkylating agents 93 . More recently, highly specific inhibitors of Pol β have been developed that dramatically potentiate the sensitivity of colon cancer cells to temozolomide 94, 95 . Further synergism was observed on treatment with both Pol β inhibitors and temozolomide in cells lacking the HR factor BRCA2, underscoring the importance of multiple DNA repair pathways in repairing alkylation damage 96 . Finally, chemical modulation of another DNA repair enzyme, poly(ADP-ribose) polymerase (PARP) has emerged as a potential chemotherapeutic strategy to increase cellular sensitivity to alkylating agents (reviewed in REFS 97, 98) . PARP has an important role in the proper repair of SSBs that are generated during BER by signalling the presence of SSBs to downstream enzymatic repair machinery. The binding of PARP to SSBs leads to PARP activation and to the synthesis of poly(ADP-ribose) chains that facilitate the recruitment of XRCC1, Pol β and ligase to the DNA strand break. Importantly, Parp1 -/-mice and Parp1
-/-cells exhibit increased sensitivity to various alkylating agents 99, 100 , indicating that PARP inhibition can serve as an effective combination therapy with monofunctional alkylating agents. Moreover, the discovery that the treatment of BRCA1-or BRCA2-deficient tumour cells with PARP inhibitors results in synthetic lethality has strengthened interest in these inhibitors for single-agent therapies 101, 102 . However, it should be noted that, similar to the consequences of altering AAG activity, PARP inhibition can result in dramatically different phenotypic outcomes depending on the cellular context. For example, PARP inhibition in cells with imbalanced BER (owing to altered AAG and Pol β activities) results in resistance to alkylating agents, rather than in the alkylation sensitivity that is observed in other cellular contexts 103 . Thus, it will be clinically important to investigate overall BER function in tumours and patients before using PARP inhibitors 104 .
Protecting against the effects of O 6 meG lesions As mentioned above, the O 6 meG lesion is the predominant O-methyl adduct although it contributes only ~5% of the total lesions that are induced by methylating agents, compared with the 60-80% represented by N-methyl adducts. However, depending on the particular cell type and the genetic background of the organism, the O 6 meG lesion can have dramatic biological effects by eliciting most of the mutagenic and cytotoxic effects that are associated with S N 1 chemotherapeutic alkylating drugs. Similar to the complex biological response caused by 3meA adducts, it is the interplay between numerous factors in several different pathways that determines the final biological outcome in response to O 6 meG. The MGMT alkyltransferase DNA repair protein has a pivotal role in governing the fate of organisms that are exposed to chemotherapeutic alkylating agents by directly reversing O 6 meG lesions in genomic DNA 17, 105 (FIGS 3,4) .
The protective effect of MGMT has been demonstrated in a striking manner by using transgenic mice that overexpress either the human or the bacterial homologue of MGMT in the thymus, liver or colon; these MGMT-overexpressing mice exhibit a significant reduction in alkylation-induced thymic lymphoma, liver tumour development and colon carcinogenesis [106] [107] [108] [109] [110] [111] (TABLE 2) . Increased expression of MGMT in skin keratinocytes can also confer protection against epidermal papilloma and tumour formation that is induced by topical application of alkylating agents [112] [113] [114] . Even in cancer-prone mouse models, increasing the level of MGMT activity is sufficient to decrease spontaneous hepatocellular carcinoma, as well as alkylation-induced lymphoma, development 110, [115] [116] [117] [118] . Remarkably, mice
Box 1 | The role of base excision repair in neurodegeneration
The link between DNA repair and neurodegeneration (reviewed in REF. 196) was first established by the discovery of premature nerve cell death and neurological symptoms in patients with xeroderma pigmentosum 197 . This connection was strengthened when mutations in other DNA damage-response proteins were found to be responsible for the human neurodegenerative syndromes ataxia telangiectasia and ataxia telangiectasia-like disease 198 . Evidence suggests that imbalanced base excision repair (BER) may also have a role in Alzheimer's disease, as the activity of numerous BER proteins is altered in patients with Alzheimer's disease [199] [200] [201] . Specifically, patients with Alzheimer's disease exhibit decreased DNA glycosylase activity and reduced gap-filling activity 202 . Intriguingly, the alteration of BER activity in patients with Alzheimer's disease may be due to the exacerbated age-dependent accumulation of transition metals in diseased brains; these transition metals have been shown to inhibit the function of certain DNA glycosylases 203, 204 . More recently, additional neurodegenerative syndromes have been linked to mutations in the DNA repair proteins aprataxin (APTX) and tyrosyl-DNA phosphodiesterase 1 (TDP1) 205, 206 . APTX and TDP1 process DNA ends following abortive enzymatic reactions; patients with these mutations cannot complete ligation of single-strand DNA breaks (SSBs). As SSBs are BER intermediates, it is hypothesized that an imbalance in BER may contribute to the pathology of these disorders. Illustrating the importance of SSB repair in neurons, brain-specific depletion of the BER protein XRCC1 results in increased DNA damage, cerebellar interneuron degeneration and ultimately a seizure phenotype that is similar to epilepsy 207 . Finally, the mutUNG-transgenic mouse model clearly demonstrates the neurotoxicity of BER intermediates 208 ; these mice exhibit a drastic increase in apyrimidinic or apurinic (AP) sites in mitochondrial DNA of the mouse forebrain, ultimately resulting in apoptosis and progressive neuronal atrophy in the hippocampus, culminating with altered cognition and anxiety-like behaviours 208 . Imbalanced BER may also have a role in neurodegeneration following treatment with an alkylating agent. The treatment of mice with methyl methanesulphonate (MMS) results in severe retinal degeneration 30 . Strikingly, MMS-induced retinal degeneration is completely suppressed in alkyladenine DNA glycosylase (Aag)-knockout mice, and is enhanced in AAG transgenic (AAG-Tg) mice, indicating that AAG-mediated initiation of BER is essential for this degeneration 30 (FIG. 5) . A similar phenomenon is observed in cerebellar granule cells; the treatment of mice with an alkylating agent results in extreme cerebellar toxicity and severely diminished motor function 119 (L.D.S., unpublished observations). Further demonstrating the importance of the BER pathway in mediating neurodegeneration, Aag -/-mice are significantly protected against, and AAG-Tg are more susceptible to, alkylation-mediated cerebellar toxicity 119 (L.D.S., unpublished observations). Together, these studies implicate an intriguing role for imbalanced BER in neurodegeneration.
Pancytopenia
Severe reduction in the number of all blood cell types, including red and white blood cells and platelets.
Myelosuppression
Inhibition of blood cell production in the bone marrow.
overexpressing MGMT exhibit significant preservation of cerebellar development and motor function after treatment with alkylating agents, indicating that MGMT can also protect against alkylating agent-induced toxicity in the brain 119 . Thus, unlike AAG overexpression that sensitizes many cell types to alkylating agents by producing a BER imbalance, the overexpression of MGMT increases cellular resistance to alkylating agents by increasing the amount of direct repair activity in the cell.
On the basis of the protective effects of MGMT expression, it is not surprising that loss of MGMT expression can adversely affect survival after exposure to alkylating agents. Indeed, Mgmt -/-mice exhibit increased levels of cell death in rapidly proliferating tissues such as bone marrow, intestine, thymus and spleen after treatment with alkylating agents (TABLE 2) . The tremendous loss of leukocytes and platelets in the haematopoietic stem cell compartment leads to significant ablation of myeloid and lymphoid tissue in Mgmt -/-mice that are treated with alkylating agents [120] [121] [122] . Notably, the severe pancytopenia that develops in Mgmt -/-mice after alkylation treatment is lethal and can only be rescued by bone marrow transplantation 123 . Neuronal cell development in the cerebellum and motor function are also severely disturbed in Mgmt -/-mice that are treated with alkylating agents, which is consistent with a protective function of MGMT in the brain 119 . In addition to severe tissue loss, treatment of Mgmt -/-mice with alkylating agents results in a large number of thymic lymphomas, as well as in colon carcinomas that are not detected in wild-type mice that are treated with the same dose of alkylating agents 55, [124] [125] [126] . Notably, many types of tumours, including brain, breast, colon and lung tumours, have increased MGMT activity when compared with the corresponding normal tissue (reviewed in REF. 127 ). Although the relationship between MGMT activity and clinical outcome remains to be determined for many cancer models, a significant inverse correlation between MGMT expression and patient response has been demonstrated for several types of brain tumour (TABLE 1) . In particular, numerous studies have found that paediatric brain tumours exhibit much higher MGMT activity than adult tumours 128, 129 , leading to a poor response of paediatric tumours to alkylating agents such as temozolomide. Moreover, epigenetic silencing of MGMT expression by promoter methylation correlates with a better therapeutic response in patients with glioblastoma 130 , which is consistent with decreased MGMT levels conferring sensitivity to S N 1-alkylating agents 131 .
Imbalancing MGMT activity to improve chemotherapy. The dramatic effect of MGMT activity on cellular sensitivity and resistance to alkylating agents suggests that the modulation of MGMT levels could be used to enhance chemotherapy with alkylating drugs. For example, the inhibition of MGMT activity could be used in the clinic to sensitize cancer cells to alkylating agent-induced toxicity. Indeed, several chemical inhibitors of MGMT activity have been developed and shown to improve the efficacy of alkylating agent-based chemotherapy 105, 132 133, 134 . Unfortunately, MGMT inhibition in non-tumour cells can lead to myelosuppression, a complication that must be rectified in order to specifically target cancer tissues for sensitization to alkylating agents 135, 136 . As a corollary to decreasing MGMT activity in cancer cells, increasing MGMT activity in non-cancer cells could improve chemotherapeutic efficacy by protecting normal, bystander cells from alkylating agent-induced cell death and mutation. For example, increasing MGMT activity in mouse bone marrow cells can reduce the myelosuppression that is associated with alkylating agent treatment, suggesting a possible approach for protecting cancer patients from chemotherapy-associated bone marrow toxicity [137] [138] [139] [140] . Of clinical relevance, enhancing MGMT repair activity in haematopoietic cells by stable MGMT overexpression has been proven to increase cellular survival during a clinical chemotherapy regimen by mitigating the toxic effects of O 6 meG adducts 141 . Chemoprotection has been further demonstrated using immunodeficient mice engrafted with human haematopoietic stem cells overexpressing MGMT, as well as with large animal canine models [142] [143] [144] [145] [146] , suggesting feasibility in cancer patients. In addition, increased MGMT expression in bone marrow cells would be expected to reduce the incidence of therapy-related secondary cancers. Ideally, an O Multiple cellular pathways determine the biological effects of O 6 meG lesions. Although MGMT is a major protective factor against the deleterious consequences of O-alkylation DNA damage, the relative levels of MGMT in a particular tissue are not necessarily predictive of its sensitivity to alkylating agents when MGMT is absent from that tissue. For example, wild-type bone marrow cells express extremely low levels of MGMT (~100-fold lower than liver cells) but they are one of the most sensitive tissues to alkylating agents in Mgmt -/-mice 121 (FIG. 6) . As described below, the formation of O 6 meG:T mispairs has dramatic biological consequences by recruiting the MMR pathway, which in turn triggers a cascade of DNA-processing events that can lead to replication fork collapse, SCEs, chromosome aberrations and cell death.
Among the cellular factors that govern sensitivity to chemotherapeutic alkylating agents, the MMR pathway has emerged as a key determinant of the biological effects of O-alkylation damage (reviewed in REF. 155 ). Although the mechanism by which MMR combines with O-alkyl lesions to modulate the cytotoxicity of alkylating agents is not completely understood, numerous studies have established that the recognition of O 6 meG:T mispairs by the MUTSα subunit (which is comprised of MSH2 and MSH6) of the MMR pathway is a crucial step for the initiation of programmed cell death in response to alkylation damage [156] [157] [158] [159] [160] . A possible mechanism to explain the role of MMR in alkylating agent-induced cell death involves the repeated processing and regeneration of O 6 meG:T mispairs, ultimately leading to cytotoxic DSBs (FIG. 6 ). In this model, the MMR machinery would excise the newly synthesized DNA strand containing the mismatched thymine, but would then reinsert another thymine opposite the O 6 meG, thus leading to futile cycles of MMR. This constant MMR-dependent processing of DNA at O 6 meG:T mispairs would promote the formation of single-stranded DNA gaps 161 that can collapse DNA replication forks, leading to the formation of DSBs 162 . The conversion of O 6 meG lesions into highly cytotoxic DSBs is thought to be the ultimate trigger for cell death by the apoptotic pathway.
In response to collapsed replication forks or DSBs that are caused by aberrant MMR-dependent processing, error-free recombination by the HR pathway can provide an additional cellular survival mechanism against the cytotoxic effects of O-alkyl lesions [163] [164] [165] (FIG. 6) . Consistent with the formation of DSBs caused by MMR-dependent processing and subsequent repair by HR, cells that are deficient in the HR pathway display increased sensitivity to S N 1-alkylating agents [166] [167] [168] . Although the HR pathway promotes survival by resolving DNA repair intermediates or DSBs caused by MMR processing, this pathway increases the amount of recombination and SCEs 153 . Indeed, MGMT-deficient cells treated with non-toxic doses of S N 1-alkylating agents display SCEs after two rounds of replication 169 , which is consistent with recombination occurring at DNA strand breaks that are induced by aberrant MMR processing. Thus, in addition to MGMT, at least three different DNA damage repair or bypass pathways (MMR, TLS and HR) can converge at sites of O-alkylation damage to influence the final biological effects that are caused by a single type of damaged DNA base lesion (FIG. 6) .
In addition to MMR-induced DSB formation, the recognition of O 6 meG:T mispairs by MMR proteins could serve as a sensor for DNA alkylation damage that directly signals for cell death via apoptosis (FIG. 6) . In support of MMR-dependent DNA damage signalling, the MUTSα complex can physically interact with and activate the DNA damage checkpoint kinase ataxia-telangiectasia and Rad3-related (ATR) after the formation of O 6 meG:T mispairs 170 . Although it is not known whether ATR activation by MMR is sufficient to trigger apoptosis, it is possible that a combination of MMR signalling and MMR-dependent processing of O 6 meG lesions contributes to the activation of apoptosis. Importantly, in either scenario, alkylation-induced cell death is dependent on the MMR-dependent recognition of O 6 meG lesions. Thus, in contrast to MGMT, for which the inhibition or loss of expression increases cellular sensitivity to chemotherapeutic alkylating agents, loss of the MMR pathway produces cells that tolerate O-alkyl adducts and that are remarkably resistant to the killing effects of S N 1-alkylating agents 160, [171] [172] [173] [174] [175] . The protective effect conferred by the loss of the MMR pathway has been observed in many different cell types, as well as in tissues such as the intestine, colon and haematopoietic stem cell compartment [176] [177] [178] [179] [180] [181] . Notably, the loss of MMR can completely rescue the sensitivity of Mgmt -/-mice to alkylating agents, indicating that MMR-dependent recognition of O 6 meG lesions is the major contributing factor to cell death and that an entire organism can survive with unrepaired O 6 meG lesions present in its genomic DNA as long as these lesions are not processed by the MMR machinery 122, 182 . However, as expected by the mutagenic properties of O-alkylation damage, mice that are deficient in both MMR and MGMT are extremely sensitive to alkylation-induced lymphoma, demonstrating that the O 6 meG adducts that escape MMR processing can generate mutations that lead to cancer 177, 181, 182 . Collectively, these studies indicate that, in certain cellular contexts, O-alkyl lesions are the main contributors to the cytotoxicity and mutagenicity of chemotherapeutic alkylating agents, with MGMT, MMR, TLS and HR the pivotal factors in determining eventual toxicity. Importantly, deregulation in any of these pathways, either through inactivation or through overexpression, has been linked to increased cancer susceptibility or to cancer resistance to chemotherapeutic alkylating agents (reviewed in (TABLE 1) .
Concluding remarks and future perspectives
It is becoming clear that the response of an organism to chemotherapeutic alkylating agents is dictated by the coordination of factors within a particular DNA repair pathway, as well as by the interplay between different DNA repair pathways. As discussed above, an imbalance in just a single factor can have severe consequences to the health of an organism when exposed to a chemotherapeutic alkylating agent, and, in some cases, the actions of DNA repair proteins can be highly toxic to the cell rather than protective. Cellular imbalances can arise from genetic differences (mutations and polymorphisms) or epigenetic variation (heterochromatic silencing and microRNA-mediated transcriptional regulation) that can alter the levels of protein expression or activity within a DNA repair pathway [188] [189] [190] [191] . Not surprisingly, these changes in gene expression and regulation can account for the extensive range of responses to alkylating agents exhibited by different cells and tissues within an individual (intra-individual variation), as well as the broad differences between individuals (inter-individual variation) 192, 193 . Thus, the next step in understanding how cells respond to chemotherapeutic alkylating agents will involve systems-level analyses (such as genomics, transcriptomics and proteomics) to provide a global overview of how the levels of DNA repair components can ultimately affect alkylation sensitivity or resistance. The combination of systems-level approaches will improve personalized chemotherapeutic regimens by pinpointing the threshold response of an individual, thereby reducing toxicity or mutagenicity while maximizing tumour cell killing efficiency 104 . In addition to the known DNA repair pathways that are described above, toxicogenomic studies have revealed novel cellular factors that have major roles in determining the response of an organism to alkylating agents [193] [194] [195] . The identification of pathways outside DNA repair that modulate the intra-individual and inter-individual responses to alkylating agents will be of paramount importance for the development of novel chemotherapy regimens that target non-DNA repair pathways with the potential for reducing toxicity and carcinogenicity. Further investigation into the cellular factors and pathways that participate in the repair and response to alkylating agents will provide key insight into the proper use of chemotherapeutic drugs based on alkylating agents. Moreover, these cellular factors and pathways could be altered in normal or cancer cells to improve chemotherapies that are based on alkylating agents.
